Which groups of people are not suitable for taking everolimus (Afinitor)?

Everolimus is primarily metabolized by the liver and partially excreted by the kidneys. Therefore, it is not recommended or should be used with caution in patients with severe hepatic insufficiency (Child-Pugh C grade) or severe renal impairment. Accumulation of drugs in the body may increase the risk of toxicity, such as hematological abnormalities, infections, and metabolic disorders. Liver and renal function should be evaluated before use, and the dose should be adjusted or alternative treatment options selected if necessary.

Everolimus is a mTOR inhibitor that has immunosuppressive effects and may increase the risk of infection. In patients with a history of active infection, AIDS, or other severe immunodeficiencies, the use of everolimus may cause the infection to worsen or become difficult to control. Therefore, use in this group of people should be avoided or risk assessment and preventive treatment should be carried out under strict supervision.

Everolimus may have teratogenic effects on the fetus and can be excreted through breast milk, posing potential risks to the baby. Therefore, it is contraindicated for pregnant and lactating women. Women of childbearing age should take effective contraceptive measures before use to ensure the safety of the drug, and conduct regular pregnancy monitoring during treatment.

It is contraindicated in patients known to be allergic to everolimus or its excipients to prevent the occurrence of severe allergic reactions. At the same time, everolimus may cause the aggravation of hypertension or cardiovascular events, and should be used with caution in patients with severe heart failure or unstable heart disease. If necessary, adjust the dose or choose an alternative under the guidance of a cardiovascular doctor to ensure the safety of treatment.

Reference materials:https://www.drugs.com/